Bac 3 Gel is positioning its synthetic mucus-mimicking biomaterial platform as a way to grow harder-to-culture microbiome communities at higher yield than conventional bioreactor approaches. In an interview-style report, CEO Sebastião van Uden said the gel is designed to reproduce key structural and chemical properties of human mucus and can be customized for multiple body sites. The company claims up to 92% species recovery from microbiome samples versus 2–3% with standard methods, targeting academia, biotech, pharma research, and nutrition applications. The go-to-market path described includes research tools first, then a supplement partnership stage, and later development of live biotherapeutics. Bac 3 Gel also referenced using AI for digital-twin style testing of how particular strains could influence microbiome populations across geographies and diets.